Histamine H3 Receptor Antagonists Go to Clinics
Authors:
- 1 January 2008
- journal article
- review article
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 31 (12) , 2163-2181
Abstract
Within the recent years novel lead optimisations for histamine H3 receptor antagonists made their way from bench to bedside. Structure–activity relationships, cross-affinities and side effects as well as pharmacokinetic profiling will be discussed on selected promising compound series. Due to diversity in potential therapeutic applications and in some cases a controversial debate, different indications will be highlighted with the potential and the problems of the test compounds, e.g. sleep-wake disorders, attention-deficient hyperactivity disorder, epilepsy, cognitive impairment, schizophrenia, obesity and neuropathic pain. First data published on clinical trials phase II (IIb) are presented showing proof of concept of H3 receptor antagonists in narcolepsy and photo-induced epilepsy.Keywords
This publication has 243 references indexed in Scilit:
- Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal functionNeuropharmacology, 2008
- Immunohistochemical localization of histamine H3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: Potential antinociceptive targetsPain, 2007
- Histamine H3-receptor signaling in cardiac sympathetic nerves: Identification of a novel MAPK-PLA2-COX-PGE2-EP3R pathwayBiochemical Pharmacology, 2007
- Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: evaluation of a potential PET ligandNuclear Medicine and Biology, 2006
- Cytochrom-P450-Enzyme und ihre Bedeutung für MedikamenteninteraktionenDer Anaesthesist, 2002
- The Rat H3 Receptor: Gene Organization and Multiple IsoformsBiochemical and Biophysical Research Communications, 2001
- Drug-protein interactions: Two-site binding of heterocyclic ligands to a monomeric hemoglobinJournal of Inorganic Biochemistry, 1996
- Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptomsSchizophrenia Research, 1995
- Azines and Diazines as Potential Histamine H3‐Receptor AntagonistsArchiv der Pharmazie, 1995
- Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptorsJournal of Neural Transmission, 1993